Search research articles
Contact Us
Filters
Showing results (11-20 of 215) with videos related to
Page
of 22
Sort By:
Pharmacoepidemiology and Drug Safety
|
July 17, 2004
Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit
Michael A Fischer, Jerry Avorn
Archives of Dermatology
|
April 18, 2007
Topical calcineurin inhibitors revisited
Abrar Qureshi, Michael A Fischer
The Virtual Mentor : VM
|
December 13, 2012
Educating Trainees about the Cost of Medications
Michael A Fischer, Jerry Avorn
American Journal of Public Health
|
April 21, 2017
Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics
Joshua M Liao, Michael A Fischer
Archives of Dermatology
|
May 17, 2006
Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks
Abrar A Qureshi, Michael A Fischer
The New England Journal of Medicine
|
September 24, 2015
Early Patterns of Sofosbuvir Utilization by State Medicaid Programs
Joshua M Liao, Michael A Fischer
Journal of General Internal Medicine
|
September 19, 2019
The Future of the Patient-Centered Outcomes Research Institute (PCORI)
Michael A Fischer, Steven M Asch
JAMA Internal Medicine
|
August 15, 2018
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Amputation: Results and Challenges From the Real World
Michael Fralick, Elisabetta Patorno, Michael A Fischer
Health Affairs (Project Hope)
|
July 13, 2006
The rise and fall of Natrecor for congestive heart failure: implications for drug policy
Aaron S Kesselheim, Michael A Fischer, Jerry Avorn
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
November 6, 2020
Educating community clinicians using principles of academic detailing in an evolving landscape
Amanda G Kennedy, Loren Regier, Michael A Fischer
Page
of 22
Search research articles
Search
Showing results (11-20 of 215) with videos related to
Sort By:
Page
of 22
Pharmacoepidemiology and Drug Safety
|
July 17, 2004
Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit
Michael A Fischer, Jerry Avorn
Archives of Dermatology
|
April 18, 2007
Topical calcineurin inhibitors revisited
Abrar Qureshi, Michael A Fischer
The Virtual Mentor : VM
|
December 13, 2012
Educating Trainees about the Cost of Medications
Michael A Fischer, Jerry Avorn
American Journal of Public Health
|
April 21, 2017
Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics
Joshua M Liao, Michael A Fischer
Archives of Dermatology
|
May 17, 2006
Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks
Abrar A Qureshi, Michael A Fischer
The New England Journal of Medicine
|
September 24, 2015
Early Patterns of Sofosbuvir Utilization by State Medicaid Programs
Joshua M Liao, Michael A Fischer
Journal of General Internal Medicine
|
September 19, 2019
The Future of the Patient-Centered Outcomes Research Institute (PCORI)
Michael A Fischer, Steven M Asch
JAMA Internal Medicine
|
August 15, 2018
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Amputation: Results and Challenges From the Real World
Michael Fralick, Elisabetta Patorno, Michael A Fischer
Health Affairs (Project Hope)
|
July 13, 2006
The rise and fall of Natrecor for congestive heart failure: implications for drug policy
Aaron S Kesselheim, Michael A Fischer, Jerry Avorn
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
November 6, 2020
Educating community clinicians using principles of academic detailing in an evolving landscape
Amanda G Kennedy, Loren Regier, Michael A Fischer
Page
of 22